MYCN and neuroblastoma: These data demonstrate that high-risk neuroblastoma cells have enhanced pralatrexate sensitivity compared to methotrexate and that pralatrexate inhibits both MYCN amplified and non-MYCN amplified neuroblastoma growth in the low nanomolar range in vitro.